Medicare Proposes Earlier Deadline For Rx Add-On Payment Candidates
Executive Summary
Starting in fiscal year 2025, products would need to meet an earlier, May deadline for FDA approval in order to be eligible for enhanced payments in the Hospital Inpatient Prospective Payment System (IPPS). The change would give CMS more to handle the surge in NTAP applications.
You may also be interested in...
Janssen Seeking Medicare Add-On Payments For CAR-T Carvykti, But CMS May Be Skeptical
J&J will need to convince the Centers for Medicare and Medicaid Services that its treatment is not substantially similar to existing CAR-T’s in order to qualify for supplemental Medicare reimbursement.
When FDA Changes Your Payment Plans
Five sponsors withdrew their applications for new technology add-on payments from CMS – all due to regulatory reasons happening at the US FDA.
Antibiotic Payment Incentives: Advocates Still Looking For More
After some success in enacting new regulatory and exclusivity incentives in the US over the past decade, antibiotic research advocates are urging action on the payment/reimbursement side. One start-up CEO argues that Medicare needs to rethink its approach to payment for hospital antibiotics.